Apellis Pharmaceuticals Return on Equity

Apellis Pharmaceuticals (APLS) currently reports a ROE of 32.12%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore Apellis Pharmaceuticals's ROE history and peer comparisons.

Apellis Pharmaceuticals's ROE of 32.12% is higher than the Healthcare sector average of 29.33%. That is roughly 9.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Apellis Pharmaceuticals's current 32.12% should be judged against Healthcare norms (sector average: 29.33%) and against APLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 32.12%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Apellis Pharmaceuticals, and consider following APLS for alerts when major investors trade the stock.

Apellis Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 32.12% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing APLS with unrelated industries.